A benefit of maintenance olaparib versus placebo in prolonging PFS in first-line metastatic pancreatic cancer patients with germline BRCA1/BRCA2 mutations was observed in the Pancreas Cancer Olaparib Ongoing (POLO) phase III randomized double-blind trial [54]. The gene discussed is BRCA1; the disease is pancreatic neoplasm.